[This supersedes survey #47 from early 2006, which asked whether Tysabri or Copaxone would have larger cumulative sales from 2007-2009. That survey is being retired because it now looks hopeless for Tysabri to catch up to Copaxone during the specified time period.]
Q: Worldwide sales of Tysabri in 2009 will be:
a) Zero b) More than zero and <$250M c) $250-499M d) $500-999M e) $1B or more
Market Data 
Markets 
AI
